In a phase 2b trial conducted by Loomba et al., the administration of a selective inhibitor of apoptosis signal-regulating kinase 1 (ASK-1), selonsertib, resulted in more than one stage of fibrosis regression in patients with NASH and F2-F3 fibrosis scores [67]. Here, MAP3K5 is linked to metabolic dysfunction-associated steatohepatitis.